Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
- PMID: 20128861
- PMCID: PMC4441275
- DOI: 10.1111/j.1538-7836.2010.03792.x
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
Abstract
Summary background: Gene-based warfarin dosing algorithms have largely been developed in homogeneous populations, and their generalizability has not been established.
Objectives: We sought to assess the performance of published algorithms in a racially diverse and multiethnic sample, and determine if additional clinical variables or genetic variants associated with dose could enhance algorithm performance.
Patients and methods: In 145 compliant patients on warfarin with a goal international normalized ratio (INR) of 2-3, stable, therapeutic doses were compared with predicted doses using 12 reported algorithms that incorporated CYP2C9 and VKORC1 variants. Additional covariates tested with each model included race, concurrent medications, medications known to interact with warfarin and previously described CYP4F2, CALU and GGCX variants.
Results: The mean patient age was 67 +/- 14 years; 90 (62%) were male. Eighty-two (57%) were Caucasian, 28 (19%) African-American, 20 (14%) Hispanic and 15 (10%) Asian. The median warfarin dose was 35 mg per week (interquartile range 23-53 mg per week). Gene-based dosing algorithms explained 37-55% of the variation in warfarin dose requirements. Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.
Conclusions: Existing gene-based dosing algorithms explained between approximately one-third and one-half of the variability in warfarin dose requirements in this racially and ethnically diverse cohort. Additional clinical and recently described genetic variants associated with warfarin dose did not enhance prediction in our patient population.
Conflict of interest statement
The authors state that they have no conflict of interest.
Figures


Similar articles
-
Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3. Mol Diagn Ther. 2013. PMID: 23839801
-
Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.J Am Med Dir Assoc. 2011 Nov;12(9):633-8. doi: 10.1016/j.jamda.2010.12.006. Epub 2011 Jan 26. J Am Med Dir Assoc. 2011. PMID: 21450231
-
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71. Pharmacogenomics. 2009. PMID: 19663669 Free PMC article.
-
Warfarin Therapy and VKORC1 and CYP Genotype.2012 Mar 8 [updated 2018 Jun 11]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2012 Mar 8 [updated 2018 Jun 11]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 28520347 Free Books & Documents. Review.
-
Genotype-guided dosing of warfarin through modeling and simulation.Eur J Pharm Sci. 2017 Nov 15;109S:S9-S14. doi: 10.1016/j.ejps.2017.05.017. Epub 2017 May 11. Eur J Pharm Sci. 2017. PMID: 28502675 Review.
Cited by
-
Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients.Clin Appl Thromb Hemost. 2018 Mar;24(2):353-359. doi: 10.1177/1076029616683046. Epub 2017 Jan 4. Clin Appl Thromb Hemost. 2018. PMID: 28049362 Free PMC article.
-
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.Pharmacogenomics. 2012 Mar;13(4):407-18. doi: 10.2217/pgs.11.164. Epub 2012 Feb 13. Pharmacogenomics. 2012. PMID: 22329724 Free PMC article.
-
Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans.Front Pharmacol. 2021 Oct 29;12:749786. doi: 10.3389/fphar.2021.749786. eCollection 2021. Front Pharmacol. 2021. PMID: 34776967 Free PMC article.
-
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.Clin Pharmacol Ther. 2019 Jun;105(6):1477-1491. doi: 10.1002/cpt.1323. Epub 2019 Feb 17. Clin Pharmacol Ther. 2019. PMID: 30506689 Free PMC article.
-
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.Clin Pharmacol Ther. 2020 Jun;107(6):1420-1433. doi: 10.1002/cpt.1755. Epub 2020 Jan 28. Clin Pharmacol Ther. 2020. PMID: 31869433 Free PMC article.
References
-
- Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633–52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases